HRP20201662T1 - Derivati diamino piridina - Google Patents
Derivati diamino piridina Download PDFInfo
- Publication number
- HRP20201662T1 HRP20201662T1 HRP20201662TT HRP20201662T HRP20201662T1 HR P20201662 T1 HRP20201662 T1 HR P20201662T1 HR P20201662T T HRP20201662T T HR P20201662TT HR P20201662 T HRP20201662 T HR P20201662T HR P20201662 T1 HRP20201662 T1 HR P20201662T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- hal
- amino
- Prior art date
Links
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical class NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- DMOUHLFECGLYQJ-UHFFFAOYSA-N 4-(2-chloroanilino)-6-(pyridin-2-ylamino)pyridine-3-carboxamide Chemical compound ClC1=C(C=CC=C1)NC1=CC(=NC=C1C(=O)N)NC1=NC=CC=C1 DMOUHLFECGLYQJ-UHFFFAOYSA-N 0.000 claims 1
- OYWNKAAPXTYEBN-UHFFFAOYSA-N 4-(2-chloroanilino)-6-[(6-methylpyridin-2-yl)amino]pyridine-3-carboxamide Chemical compound ClC1=C(C=CC=C1)NC1=CC(=NC=C1C(=O)N)NC1=NC(=CC=C1)C OYWNKAAPXTYEBN-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Spoj, naznačen time, što je predstavljen formulom (I) ili njegova farmaceutski prihvatljiva sol;
[image]
u kojoj,
R1 je H ili C1-C6alkil; i
Hal je halogen.
2. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, što Hal je klor ili fluor.
3. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, što Hal je klor.
4. Spoj prema patentnom zahtjevu 1, 2 ili 3, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R1 je metil.
5. Spoj prema patentnom zahtjevu 1, 2 ili 3, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R1 je vodik.
6. Spoj prema patentnom zahtjevu 1, 2, 3, ili 4 ili njegova farmaceutski prihvatljiva sol, naznačen time, što R1 je metil na položaju 6 pridruženog piridinskog prstena.
7. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, što je spoj odabran iz niza koji čine
4-((2-klorofenil)amino)-6-(piridin-2-ilamino)nikotinamid; i
4-((2-klorofenil)amino)-6-((6-metilpiridin-2-il)amino)nikotinamid.
8. Farmaceutski pripravak, naznačen time, što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 7 i jedan ili više farmaceutski prihvatljivih nosača.
9. Kombinacija, naznačena time, što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 7 ili njegove farmaceutski prihvatljive soli i jedno ili više terapeutski aktivnih ko-agensa.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, naznačen time, što se upotrebljava kao modulator JAK.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, naznačen time, što se upotrebljava kao lijek.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time, što se upotrebljava u liječenju atopijskog dermatitisa ili psorijaze.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15196542 | 2015-11-26 | ||
| PCT/IB2016/057105 WO2017089985A1 (en) | 2015-11-26 | 2016-11-24 | Diamino pyridine derivatives |
| EP16805218.1A EP3380465B1 (en) | 2015-11-26 | 2016-11-24 | Diamino pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201662T1 true HRP20201662T1 (hr) | 2020-12-25 |
Family
ID=54705130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201662TT HRP20201662T1 (hr) | 2015-11-26 | 2020-10-14 | Derivati diamino piridina |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10570096B2 (hr) |
| EP (2) | EP3757097B1 (hr) |
| JP (1) | JP6634157B2 (hr) |
| KR (1) | KR102097878B1 (hr) |
| CN (2) | CN112851578A (hr) |
| AU (1) | AU2016359438B2 (hr) |
| BR (1) | BR112018009540A2 (hr) |
| CA (1) | CA3005159A1 (hr) |
| CL (1) | CL2018001370A1 (hr) |
| CO (1) | CO2018005354A2 (hr) |
| CR (1) | CR20180285A (hr) |
| CU (1) | CU24506B1 (hr) |
| CY (1) | CY1123543T1 (hr) |
| DK (1) | DK3380465T3 (hr) |
| DO (1) | DOP2018000127A (hr) |
| EA (1) | EA035899B1 (hr) |
| EC (1) | ECSP18041731A (hr) |
| ES (2) | ES2916582T3 (hr) |
| HK (1) | HK1253530A1 (hr) |
| HR (1) | HRP20201662T1 (hr) |
| HU (1) | HUE052345T2 (hr) |
| IL (1) | IL259360B (hr) |
| LT (1) | LT3380465T (hr) |
| MX (1) | MX2018006495A (hr) |
| MY (1) | MY195905A (hr) |
| PE (1) | PE20181071A1 (hr) |
| PH (1) | PH12018501019A1 (hr) |
| PL (2) | PL3757097T3 (hr) |
| PT (2) | PT3380465T (hr) |
| RS (1) | RS60946B1 (hr) |
| RU (2) | RU2020124922A (hr) |
| SA (1) | SA518391657B1 (hr) |
| SG (1) | SG11201803760VA (hr) |
| SI (1) | SI3380465T1 (hr) |
| WO (1) | WO2017089985A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3380465T (pt) * | 2015-11-26 | 2020-10-23 | Novartis Ag | Derivados de diamino piridina |
| BR112021013377A2 (pt) | 2019-01-11 | 2021-09-14 | Novartis Ag | Inibidores de lta4h para o tratamento de hidradenite supurativa |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| KR101149295B1 (ko) * | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| DK2134689T3 (da) * | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
| EP2361902A4 (en) | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
| CA2745004C (en) | 2008-11-28 | 2014-07-15 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| ES2473584T3 (es) | 2009-01-23 | 2014-07-07 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| EP2909174A1 (en) | 2012-10-19 | 2015-08-26 | F. Hoffmann-La Roche AG | Inhibitors of syk |
| ES2914793T3 (es) * | 2012-11-08 | 2022-06-16 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa |
| WO2014074675A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| MX2015005272A (es) * | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| JP2015014960A (ja) | 2013-07-05 | 2015-01-22 | ソニー株式会社 | 情報処理装置、および記憶媒体 |
| AU2014339897A1 (en) | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| JP2018502837A (ja) | 2014-12-03 | 2018-02-01 | アールエックスアイ ファーマシューティカルズ コーポレーション | 遺伝子調節アプローチを用いた円形脱毛症の処置方法 |
| PT3380465T (pt) * | 2015-11-26 | 2020-10-23 | Novartis Ag | Derivados de diamino piridina |
-
2016
- 2016-11-24 PT PT168052181T patent/PT3380465T/pt unknown
- 2016-11-24 EP EP20185507.9A patent/EP3757097B1/en active Active
- 2016-11-24 HU HUE16805218A patent/HUE052345T2/hu unknown
- 2016-11-24 ES ES20185507T patent/ES2916582T3/es active Active
- 2016-11-24 PT PT201855079T patent/PT3757097T/pt unknown
- 2016-11-24 PL PL20185507.9T patent/PL3757097T3/pl unknown
- 2016-11-24 US US15/778,783 patent/US10570096B2/en active Active
- 2016-11-24 CA CA3005159A patent/CA3005159A1/en not_active Abandoned
- 2016-11-24 RU RU2020124922A patent/RU2020124922A/ru unknown
- 2016-11-24 AU AU2016359438A patent/AU2016359438B2/en not_active Ceased
- 2016-11-24 SI SI201630959T patent/SI3380465T1/sl unknown
- 2016-11-24 CR CR20180285A patent/CR20180285A/es unknown
- 2016-11-24 RS RS20201234A patent/RS60946B1/sr unknown
- 2016-11-24 PL PL16805218T patent/PL3380465T3/pl unknown
- 2016-11-24 ES ES16805218T patent/ES2829052T3/es active Active
- 2016-11-24 LT LTEP16805218.1T patent/LT3380465T/lt unknown
- 2016-11-24 DK DK16805218.1T patent/DK3380465T3/da active
- 2016-11-24 WO PCT/IB2016/057105 patent/WO2017089985A1/en active Application Filing
- 2016-11-24 MX MX2018006495A patent/MX2018006495A/es unknown
- 2016-11-24 SG SG11201803760VA patent/SG11201803760VA/en unknown
- 2016-11-24 CU CU2018000044A patent/CU24506B1/es unknown
- 2016-11-24 JP JP2018527091A patent/JP6634157B2/ja active Active
- 2016-11-24 PE PE2018001004A patent/PE20181071A1/es unknown
- 2016-11-24 MY MYPI2018701770A patent/MY195905A/en unknown
- 2016-11-24 KR KR1020187014470A patent/KR102097878B1/ko active IP Right Grant
- 2016-11-24 CN CN202110135667.2A patent/CN112851578A/zh not_active Withdrawn
- 2016-11-24 RU RU2018122953A patent/RU2730007C2/ru active
- 2016-11-24 BR BR112018009540A patent/BR112018009540A2/pt not_active Application Discontinuation
- 2016-11-24 EP EP16805218.1A patent/EP3380465B1/en active Active
- 2016-11-24 EA EA201891258A patent/EA035899B1/ru not_active IP Right Cessation
- 2016-11-24 CN CN201680065351.8A patent/CN108349937B/zh active Active
-
2018
- 2018-05-14 IL IL259360A patent/IL259360B/en active IP Right Grant
- 2018-05-15 PH PH12018501019A patent/PH12018501019A1/en unknown
- 2018-05-21 DO DO2018000127A patent/DOP2018000127A/es unknown
- 2018-05-22 CL CL2018001370A patent/CL2018001370A1/es unknown
- 2018-05-22 CO CONC2018/0005354A patent/CO2018005354A2/es unknown
- 2018-05-23 SA SA518391657A patent/SA518391657B1/ar unknown
- 2018-05-31 EC ECIEPI201841731A patent/ECSP18041731A/es unknown
- 2018-10-05 HK HK18112730.0A patent/HK1253530A1/zh unknown
-
2020
- 2020-01-08 US US16/737,366 patent/US11274080B2/en active Active
- 2020-10-14 HR HRP20201662TT patent/HRP20201662T1/hr unknown
- 2020-11-03 CY CY20201101039T patent/CY1123543T1/el unknown
-
2022
- 2022-02-22 US US17/677,538 patent/US20220177432A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201662T1 (hr) | Derivati diamino piridina | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20190764T1 (hr) | Heterocikli sposobni modulirati odgovore t-stanica, i postupci za njihovu upotrebu | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| PH12017500166A1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
| NZ768373A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| EA201892415A1 (ru) | Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| CY1122500T1 (el) | Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων | |
| EA201990609A1 (ru) | Производные n-(пиридин-2-ил)пиридинсульфонамида и их применение в лечении заболеваний | |
| MX2021002257A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| HRP20191955T1 (hr) | Orvepitant za liječenje kroničnog pruritusa | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201991817A1 (ru) | Интраназальная композиция, включающая бетагистин |